Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (552)	12/3/1997 5:08:00 PM
From: Robert Mayo	Read Replies (1) \| Respond to of 1060

Cherly, Thanks for the link. I noticed BetaSite, PilaSite and MethaSite were no longer listed on Insite's web page, insitevision.com. A few months ago I asked Mike Baer what had become of the three Phase III drugs and he remarked that their fate was pretty much out of INSVs hands. Rights to two of them had been sold and final FDA approval would depend on the acquiring pharma; and the third probably didn't have a big enough market to continue to pursue approval/production. Insite's product portfolio still looks good, development news is also good, and nobody is paying attention. It's frustrating. It's been frustrating for two years. Hopefully, Kumar will get the major deals done, we'll have a good H&Q conference and some money managers will finally pay attention. Don't know if 208 will beat 205 to market. I'll try to find out. Bob

To: Cheryl Galt who wrote (552)	12/4/1997 5:17:00 PM
From: Robert Mayo	Respond to of 1060

Cheryl, Quick follow-up. First of all, you were right about ISV 208 getting to market before ISV 205. Here's a brief synopsis of a conversation I had with Mike Baer today. Note that I did not discuss all of INSV's product portfolio. ISV 900 should reach the market in 1998. Estimated annual revenues from Primary Open Angle Glaucoma (POAG) test are $100M U.S. and $200M worldwide. Estimated revenues from the congenital glaucoma test test are $40M U.S. and $100M worldwide. ISV 611 should reach the market in 2000/2001. Estimated annual revenues are $100M U.S. and $200M worldwide. ISV 208 should reach the market in 2000. Estimated annual revenues are $40M U.S. and $100M worldwide. ISV 205 should reach the market in 2002/2003. Estimated annual rtevenues are $250M U.S. and $500M worldwide. Figure Insuite will receive royalty payments between 15% and 35%. Bob